Life Science Partnering
Today at the partnering 360® blog, Merck Serono shares a few of the ways they've seen partnering change over the past few years. Head over to the blog and see what they think: http://www.partnering360.com/blog/2014/10/28/shifting-models-in-life-science-partnering/ and then share how you've seen it change.
Ahead of BIO-Europe, Eric von Hoffe, President of Antigen Express, sat down with Insight. Head to the blog to find out more about their technology: http://www.partnering360.com/blog/2014/10/24/insight-into-antigen-express-immunotherapy/
We took a brief moment to check out a few of the things that BIO-Europe® companies including Apricus Biosciences, arGEN-X and RedHill Biopharma have been up to ahead of next week's event.
In this guest post on partnering360® blog from Steve Dickman, CEO, CBT Advisors, Steve examines European IPOs and the reasons more European biotechs have not made it to an IPO during the recent window. A couple of his observations regarding their performance are:
-Companies came from several European countries.
-They went public on several stock exchanges.
-Some of them raised a considerable amount of money (though typically less if they went public in Europe).
-Most of these are therapeutics companies (similar to the US IPO crop).
-With one dramatic exception, the stocks have traded down.
What do you think?
See Steve's full post at: http://bit.ly/1rvGk1i
Gain a deeper understanding of what three companies are looking for when the come to BIO-Europe®.